- Former Novartis ophthalmology program head significantly strengthens Dopavision´s management capabilities
- Company recently initiated clinical trial of novel digital therapeutic for childhood myopia
Berlin, Germany, May 25, 2022 --- Dopavision, a company pioneering the development of digital therapeutics, today announced that Mark S. Wuttke, Ph.D., has been appointed as the Company´s Chief Executive Officer. He succeeds Dopavision´s co-founder and previous Managing Director Stefan Zundel, who will remain on Dopavision´s advisory board and continue to advise the Company.
Mark Wuttke brings more than two decades of healthcare business expertise, in particular, comprehensive experience in the development and commercialization of ophthalmology products at Novartis, a global leader in eye health. He also has a strong track record in corporate strategy and branding. Prior to joining Dopavision, he worked at Novartis Pharmaceuticals for 12 years, most recently as Global Program Head in the Ophthalmology Development Unit (2015-2022), Global Brand Manager, Retina, New Products (2013-2015) and Head, Portfolio Management and Global Decision Support (2010-2013). Prior to Novartis, Mark Wuttke was a co-founder and Principal at Asten BioPharma Advisors, LLC in New York (2007-2009). Previous roles in his career include Associate Research Analyst U.S. Major Pharmaceuticals at Credit Suisse, Associate Management Consulting at Booz & Co, and Marketing & Sales Manager at Cognia Corporation. Mark Wuttke holds a Ph.D. in Biology from Temple University, Philadelphia, PA.
"We are delighted to welcome Mark on board as our new CEO," said Stefan Zundel, co-founder of Dopavision. "We have just recently transitioned to a clinical-stage company and Mark’s expertise and leadership skills will be very valuable for further advancing our lead program MyopiaX into a successful digital therapeutic. Mark is an excellent fit, a great personality, and our entire team looks forward to working with him."
"I am thrilled to join Dopavision at this crucial development stage," added Mark Wuttke, Dopavision’s CEO. "MyopiaX is designed to be the first digital therapeutic against childhood myopia and our goal is to bring this transformative treatment to patients as soon as possible. Childhood myopia is a growing public health concern and our approach aims to combine gaming with therapeutic effect, which makes it a very attractive medical solution for children and adolescents."
MyopiaX® is based on a patented, light-based technology that stimulates specific photosensitive cells of the retina, which in turn modulate retinal dopamine, a key neurotransmitter involved in eye growth. The Company has demonstrated proof-of-mechanism in preclinical models and exploratory human studies and is currently sponsoring a clinical trial in several European countries. MyopiaX® has the potential to become the first digital therapy to control childhood myopia. It is designed to achieve a medical effect while children play exciting games or use educational digital content. MyopiaX® runs on standard digital devices and is easy to use for children, requiring only minimal supervision by their parents.
###
About Dopavision
Dopavision is pioneering the development of digital therapeutics. Its lead product MyopiaX® is currently in clinical trials in Germany, Portugal, Spain, and Ireland. It is designed as a game-changing therapeutic for childhood myopia which can be seamlessly and invisibly integrated into the use of a smartphone.
Myopia, or shortsightedness, is a visual condition that affects on average every third person globally, a share that has increased rapidly during the last two decades and further accelerated during the COVID-19 pandemic. High childhood myopia imposes a significant risk to cause visual impairment and even blindness later in life. Dopavision’s goal is to develop a clinically validated therapy to halt myopia progression in children and adolescents.
Founded in 2017 by Hamed Bahmani and Stefan Zundel, Dopavision has so far raised € 15 million in venture capital and public grants and is backed by top-tier international investors such as Seventure Partners, Novartis Pharma and Boehringer Ingelheim Venture Fund. Dopavision is supported by the German government via the “Industrie-in-Klinik” program of the German Federal Ministry of Education and Research BMBF (Aktionsfeld “Gesundheitswirtschaft im Rahmenprogramm Gesundheitsforschung”, Förderkennzeichen/contract number 13GW0256).
www.dopavision.com
For further information please contact:
Dopavision GmbH
Mark Wuttke
Chief Executive Officer
info@dopavision.com
Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68
